Uni-Bio Science Group Limited ("Uni-Bio" or the "Group;" HKEx code: 690) has achieved an outstanding performance during the financial year 2013/14. The Group's topline growth beat the industry average while its two new prescription drugs, Uni-E4 and Uni-PTH, both reached major clinical milestone of completing all required clinical trials. more info >>
Uni-Bio Science Group Limited ("Uni-Bio" or the "Group;" HKEx code: 690) today reports successful Phase III clinical trial results of Uni-PTH, a once-daily prescription new drug for osteoporosis. more info >>
Uni-Bio Science Group Limited ("Uni-Bio" or the "Group") (SEHK code: 690) strengthened the composition of the Board of Directors ("Board") and senior management team to enhance business fundamentals and to initiate new business development strategies. more info >>
